Serum anti-NMDA receptor antibodies are linked to memory impairment 12 months after stroke

Arlt, Friederike A. ; Sperber, Pia S. ; Rennenberg, Regina von; Gebert, Pimrapat; Teegen, Bianca; Georgakis, Marios K. ; Fang, Rong ; Dewenter, Anna ; Görtler, Michael; Petzold, Gabor C.; Wunderlich, Silke; Zerr, Inga ; Dichgans, Martin ; Prüss, Harald ; Endres, Matthias ; Endres, Matthias ; Liman, Thomas; Nolte, Christian H.; Kerti, Lucia; Wittenberg, Tatjana; Scheitz, Jan F.; Sperber, Pia S.; Nave, Alexander H.; Kufner, Anna Ibaroule; Bode, Felix; Stösser, Sebastian; Meißner, Julius N.; Ebrahimi, Taraneh; Nordsiek, Julia; Beckonert, Niklas; Hermann, Peter; Schmitz, Matthias; Goebel, Stefan; Schütte-Schmidt, Julia; Nuhn, Sabine; Volpers, Corinna; Dechent, Peter; Bähr, Matthias; Glanz, Wenzel ; Georgakis, Marios K. ; Tiedt, Steffen ; Waegemann, Karin; Janowitz, Daniel ; Ikenberg, Benno; Bermkopf, Kathleen; Huber, Christiane; Wagner, Michael ; Neumann, Katja; Spottke, Annika ; Stöcker, Tony; Dühring, Marco; Speck, Oliver; Duezel, Emrah und Bartenstein, Peter (2024): Serum anti-NMDA receptor antibodies are linked to memory impairment 12 months after stroke. In: Molecular Psychiatry [Forthcoming]

Abstract

Patients suffering from strokes are at increased risk of developing post-stroke dementia. Serum anti-NMDA receptor autoantibodies (NMDAR1-abs) have been associated with unfavorable post-stroke outcomes. However, their effect on specific cognitive domains remains unclear. We used data from the prospective multicenter DZNE—mechanisms after stroke (DEMDAS) cohort, and measured NMDAR1-abs in serum at baseline. Cognitive function was assessed with a comprehensive neuropsychological test battery at 6- and 12-months follow-up. We employed crude and stepwise confounder adjusted linear and logistic regression models as well as generalized estimating equation models (GEE) to determine the relevance of NMDAR1-abs seropositivity on cognitive function after stroke. 10.2% (58/569) DEMDAS patients were NMDAR1-abs seropositive (IgM:n = 44/IgA:n = 21/IgG:n = 2). Seropositivity was not associated with global cognitive impairment after stroke. However, NMDAR1-abs seropositive patients performed lower in the memory domain (βadjusted = −0.11; 95%CI = −0.57 to −0.03) and were at increased risk for memory impairment (ORadjusted = 3.8; 95%CI = 1.33–10.82) compared to seronegative patients, 12 months after stroke. Further, NMDAR1-abs were linked to memory impairment over time in GEE from 6- to 12-months follow-up (ORadjusted = 2.41; 95%CI = 1.05–5.49). Our data suggests that NMDAR1-abs contribute to memory dysfunction 1 year after stroke while not affecting other cognitive subdomains. Hence, antineuronal autoimmunity may be involved in distinct mechanisms of post-stroke memory impairment. Clinical trial name and registration number: The Determinants of Dementia After Stroke (DEMDAS; study identifier on clinical trials.gov: NCT01334749)

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin > Munich Cluster for Systems Neurology (SyNergy) ; Medizin > Institut für Schlaganfall- und Demenzforschung (ISD)
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1359-4184
• Sprache: Englisch
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198